Lead author: Andrea O. Rossetti, andrea. rossetti@chuv.ch Three part clinical question: Patients: Adults (>16 years) in refractory status epilepticus not due to anoxia. Intervention: Treatment with propofol or barbiturates. Outcome: The primary outcome was successful control of seizures using burst-suppression as the measure. The secondary outcomes were: functional scores at day 21 and three months; duration of mechanical ventilation; incidence of thromboembolism, infection or hypotension; and incidence of propofol infusion syndrome or other severe complications.
MeSH search terms: Status epilepticus, propofol, barbiturates.
The study: A multi-centre, international, single-masked, randomised trial.
The study patients: The initial intention was to recruit 150 patients. In total, 24 patients were recruited from five different centres. One of the patients recovered spontaneously prior to randomisation, therefore 23 patients were included in the final analysis. Inclusion criteria: Patients >16 years in refractory status epilepticus that was not due to anoxia. Exclusion criteria: Patients who were pregnant, or had known mitochondrial disorders or egg allergy or who, on admission, were found to have hypertriglyceridaemia (>5 mmol/L) or significant rhabdomyolysis (CK>15,00 U/L).
Propofol group: Fourteen patients were randomised to receive propofol. This was given as a bolus of 2 mg/kg and then an infusion was titrated towards burst-suppression (or towards 5 mg/kg/h until EEG was available).
Barbiturate group: Nine were randomised to receive a barbiturate. In the USA-based centres, this was phenobarbital, given as a bolus of 5 mg/kg and then an infusion titrated towards burst-suppression or towards 2 mg/kg/h until EEG was available. In Switzerland, treatment in this group was with thiopental, given as a bolus of 2 mg/kg, then an infusion titrated towards burst-suppression or towards 4 mg/kg/h until EEG was available.
In both groups, a benzodiazepine was administered at low dose (either lorazepam 4 mg/24h or clonazepam 2 mg/24h) throughout the study period 'to reduce the required doses of study drug.' The second-line anti-epileptic medications were also administered in their respective usual daily doses.
EEG monitoring had to be initiated within twelve hours of starting the intervention.
The evidence
These results must be interpreted with caution given the very small numbers of patients recruited. Primary outcome: There was no significant difference in rates of seizure control between the two groups. Other outcomes: There was no significant difference in the functional outcome, mortality, rates of thrombo-embolism, infection or hypotension, severe complications or length of drug administration between the two groups. The median intubation time in patients who received propofol was significantly shorter (4 days) than in those who received barbiturates (13.5 days), p=0.03.
EBM questions: 1. Do the methods allow accurate testing of the hypothesis? No.
The principal downfall of this study is the failure to recruit sufficient numbers of patients, resulting in a severely underpowered trial. Some of the centres withdrew and in those that did recruit patients, it was acknowledged that there were several eligible patients who were not recruited. There was no clear, consistent protocol between centres and there was varied use of concomitant benzodiazepines and anti-epileptic medications between patients (although the authors state that there was no significant difference in concomitant medication administration between the two groups). There was no masking of clinicians and, therefore, a significant potential for bias. There was also failure to include a third arm looking at midazolam, another accepted treatment for refractory status epilepticus. 2. Do the statistical tests correctly test the results to allow differentiation of statistically significant results? No. In our opinion, these data should not have been subjected to statistical analysis, since there are clearly insufficient patients to produce reliable results.
A randomised trial on the treatment of refractory status epilepticus
This study failed to show a significant difference in outcome between those receiving propofol versus barbiturates in the treatment of refractory status epilepticus, except in duration of mechanical ventilation. However, due to a failure to recruit sufficient numbers of patients, the trial was significantly underpowered and we recommend caution when drawing any conclusions from the data.
Level of evidence: 1 -(RCT with a high risk of bias)
Appraised by: E Jenkinson, L Tulloch, W Tunnicliffe 3. Are the conclusions valid in light of the results? No. While the authors do acknowledge the weaknesses of the study and exercise caution, we do not feel that any conclusions should have been drawn from this data. 4. Did results get omitted? Yes. One patient was randomised to treatment but woke before this was commenced. This patient was omitted from subsequent analysis, in spite of the authors' claims of 'intention-to-treat' analysis. 5. Did they suggest further areas of research? Yes. The main suggestion was for a repeated, similar trial, involving a larger number of patients, more recruitment centres and a longer duration of recruitment, with the addition of a midazolam arm. They recommended a dedicated management centre and increased funding in order to achieve this. They also suggested a separate study to determine the appropriate duration of burst suppression that should be achieved prior to weaning treatment. 6. Did they make any recommendations based on the results and were they appropriate? Sort of… The authors wisely chose not to make any recommendations regarding the appropriate treatment drug based on these results, acknowledging the paucity of their data. Most of the suggestions that they made were regarding further areas of research (described above). They also highlighted a need for 'serial biological monitoring… particularly lactate, CK and triglycerides.' 7. Is the study relevant to my current clinical practice? Yes. We all intermittently encounter patients with refractory status epilepticus. Unfortunately this study does not allow us to make evidence-based decisions regarding treatment. 8. What level of evidence does this study represent? We do not think that it would be appropriate to assign a 'level of evidence' to this study, for the reasons that we have outlined above. 9. What grade of recommendation can I make on this study alone? We do not think that any recommendation can be made on the basis of this study. 10. What grade of recommendation can I make when this study is considered with other available evidence? Again, we do not think this study should be considered when making recommendations regarding the drug treatment of refractory status epilepticus. 11. Should I change my practice because of these results? No.
This study is not robust enough to change our management in terms of the treatment used. However, the suggestions that the authors make regarding closer biological monitoring should be considered. We feel that the most useful message we can take from this study is the difficulties entailed in conducting a large clinical trial. 12. Should I audit my current practice? No. There are no established guidelines against which we can audit.
